The Jreissati Family Pancreatic Centre at Epworth runs research studies and clinical trials covering every phase of patient diagnosis, treatment and care. The goal is to improve patient outcomes and quality of life for patients with pancreatic cancer.
Clinical trials are vital if we are to improve the survival rate for patients with pancreatic cancer. But what are they?
Talk to our pancreatic nurse coordinator
Get referred
For clinical trials, volunteer participation is essential. Results from trials will help determine if new treatments for pancreatic cancer work and if there are side effects. They're also an effective way for patients to gain access to the latest treatment options. Participation leads to advances in research, better treatments, and better patient outcomes.
When deciding if you want to take part in a clinical trial, you need to be aware of what the trial involves. You should also seek advice from your specialist before taking part. At Epworth, there are a number of clinical studies that are open to people with pancreatic cancer and are listed below.
Pancreatic cancer research at the Jreissati Family Pancreatic Centre at Epworth
Current clinical trials and special access schemes
Listing updated: 8 February 2022
Diagnosis; Line | Trial ID and Status | Study Title | Locations | Contact |
Metastatic pancreatic cancer (Stage IV) 1st and 2nd line |
NCT04481009 Recruiting |
YH003004 A phase II, multi-center, open-label study to evaluate the safety and efficacy of YH003 in combination with Toripalimab (anti-PD-1 mAb) in patients with unresectable/metastatic melanoma and pancreatic ductal adenocarcinoma (PDAC) |
Epworth Freemasons Epworth Richmond |
A/Prof Sumitra Ananda |
Resectable pancreatic cancer (Stage I-II) 1st line |
ACTRN12618000335291 Recruiting |
DYNAMIC-Pancreas Circulating Tumour DNA Analysis Informing Adjuvant Chemotherapy in Early Stage Pancreatic Cancer: A Multicentre Randomised Study. |
Epworth Freemasons Epworth Richmond |
Dr Ross Jennens |
Unresectable locally advanced pancreatic cancer (Stage III) Neo-adj |
NCT03899636 Recruiting |
DIRECT-InspIRE A Multicentre, Open-label, Innovation Study in Pancreatic Cancer Utilising the NanoKnife® System for Irreversible Electroporation (IRE) in Unresectable Stage 3 Pancreatic Adenocarcinoma |
Epworth Freemasons | Mr Brett Knowles |
Metastatic pancreatic cancer (Stage IV) 1st line |
ACTRN12621001290886 Recruiting |
ASCEND A randomised, double-blinded phase II study of gemcitabine and nab‐paclitaxel with CEND‐1 or placebo in patients with untreated metastatic pancreatic ductal adenocarcinoma |
Epworth Freemasons Epworth Richmond |
Dr Ross Jennens |
Unresectable locally advanced pancreatic cancer (Stage III) |
Special access scheme Taking referrals |
OncoSil Epworth is an accredited OncoSil treatment facility |
Epworth Richmond | A/Prof Andrew Metz Dr Peter Tagkalidis |
Current research studies
These studies may ask participants for permission to store their cancer sample, or take part in non-treatment research. Please get in touch using the online form, email or phone listed on the contact us page to take part in advancing research.
Diagnosis | Project ID and Status | Study Details | Locations | Contact |
Individuals at high risk of developing pancreatic cancer (based on demographics and family history) | EH2021-666 Recruiting |
APCSP The Australian Pancreatic Cancer Screening Program: Screening for pancreatic cancer in high risk individuals |
All Epworth sites | A/Prof Andrew Metz |
Suspected diagnosis of pancreatic cancer or cholangiocarcinoma | EH689-15 Recruiting |
VPCB The Victorian Pancreatic Cancer Biobank |
Epworth Richmond | Dr Peter Tagkalidis |
Suspected diagnosis of pancreatic or colorectal cancer | EH2019-481 Recruiting |
Organoid Biobank Establishing biobanks of colorectal and pancreatic cancer models for the pursuit of personalised therapies |
Epworth Richmond | Mr Brett Knowles |
Pancreatic cancer | EH2021-694 Recruiting |
EU-ME-PC The Endoscopic Ultrasound Molecular Evaluation of Pancreatic Cancer (EU-ME-PC): A Prospective Multicentre Cohort Trial |
All Epworth sites | Dr Allan Zimet |
Pancreatic cancer | Recruiting | MoST Molecular Screening and Therapeutics program |
All Epworth sites | A/Prof Andrew Metz |
Unresectable pancreatic cancer | EH2020-661 Recruiting |
OSCILLATE An Observational Study following Circulating tumour DNA during multi-Agent Therapy in PDAC (OSCILLATE): a hypothesis-generating, prospective cohort study |
Epworth Freemasons Epworth Richmond Epworth Eastern |
Dr Allan Zimet |
Primary carer of patient with pancreatic cancer | EH2021-729 Recruiting |
PRoCESS Pancreatic Cancer Relatives Counselling and Education Support Service trial. Assessing the effect of nurse-led counselling on participant-reported outcomes and use of medical services. |
All Epworth sites | A/Prof Andrew Metz |
Newly diagnosed pancreatic cancer | New study Recruiting |
PATHWAYS Pancreatic cancer pathways to diagnosis |
All Epworth sites | A/Prof Andrew Metz |
Databases and registries
These projects ask participants for permission to record treatment data to build better knowledge of pancreatic cancer care. Please get in touch using the online form, email or phone details on the contact us page if you see you or your patient’s diagnosis listed below.
Diagnosis | Project ID and Status | Study Details | Locations | Contact |
Newly diagnosed upper GI cancer | EH2017-227 Recruiting |
UGICR Upper Gastrointestinal Cancer Registry |
Epworth Freemasons Epworth Richmond Epworth Eastern |
Mr Brett Knowles |
Newly diagnosed pancreatic cancer | ACTRN12617001474347 Recruiting |
PURPLE Pancreatic cancer: Understanding Routine Practice and Lifting End Results. A Prospective Pancreatic Cancer Clinical Registry |
Epworth Freemasons Epworth Richmond Epworth Eastern |
A/Prof Rachel Wong |
Intraductal papillary mucinous neoplasm (PPMN) | EH2021-731 Recruiting |
IPMN IPMN Database – A tool to predict pancreatic cancer |
Epworth Eastern | A/Prof Andrew Metz |
Pancreatic cancer | EH2021-768 New study Recruiting |
PAN-ExPERT Pancreatic enzyme replacement therapy in pancreatic cancer: An implementation strategy |
Epworth Richmond | Mr Mark Cullinan |
Pancreatic or oesophageal cancer | Recruiting | PROpatient PROpatient - A registry-based randomised controlled trial (RRCT) of symptom monitoring, using patient-reported outcomes |
All Epworth sites | Mr Brett Knowles |
Phone: 03 9426 8880
Email: [email protected]